Global Alzheimer’s Disease Biomarkers Market - Strategic Insights and Forecasts (2026-2035)

The Global Alzheimer’s Disease Biomarkers Market is projected to grow at a CAGR of 13.8% during the forecast period, increasing from USD 4.09 billion in 2026 to USD 13.12 billion by 2035 due to rising demand for early and accurate Alzheimer’s diagnosis.

The Global Alzheimer’s Disease Biomarkers Market is driven by growing adoption of disease-modifying therapies, increasing preference for blood-based diagnostics, rising Alzheimer’s disease prevalence, and integration of biomarkers into drug development programs.

The Global Alzheimer’s Disease Biomarkers Market relies on biomarkers such as amyloid beta, tau, GFAP, and neurofilament light chain to enable objective detection of Alzheimer’s pathology and improve early diagnosis accuracy.

The Global Alzheimer’s Disease Biomarkers Market offers opportunities in multiplex biomarker development, primary care integration, emerging biomarker discovery, and companion diagnostic development for targeted therapies.

The Global Alzheimer’s Disease Biomarkers Market faces restraints such as limited reimbursement coverage, variability in assay standardization, and requirement for specialist interpretation in some healthcare systems.